Innate immunity drives pathogenesis of rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disease affecting similar to 1% of the general population. This disease is characterized by persistent articular inflammation and joint damage driven by the proliferating synovial tissue fibroblasts as well as neutrophil, monocyte and lymphocyte trafficking into the synovium. The factors leading to RA pathogenesis remain poorly elucidated although genetic and environmental factors have been proposed to be the main contributors to RA. The majority of the early studies focused on the role of lymphocytes and adaptive immune responses in RA. However, in the past two decades, emerging studies showed that the innate immune system plays a critical role in the onset and progression of RA pathogenesis. Various innate immune cells including monocytes, macrophages and dendritic cells are involved in inflammatory responses seen in RA patients as well as in driving the activation of the adaptive immune system, which plays a major role in the later stages of the disease. Here we focus the discussion on the role of different innate immune cells and components in initiation and progression of RA. New therapeutic approaches targeting different inflammatory pathways and innate immune cells will be highlighted here. Recent emergence and the significant roles of innate lymphoid cells and inflammasomes will be also discussed.

Automated summary

Rheumatoid arthritis is an autoimmune disease affecting about 1% of the population, with genetic and environmental factors playing key roles in its pathogenesis. While early studies focused on lymphocytes, recent research has highlighted the critical involvement of innate immune cells in the onset and progression of RA. Therapeutic approaches targeting different inflammatory pathways and immune cells, including the emerging roles of innate lymphoid cells and inflammasomes, are being explored for the treatment of RA.